Age is the leading factor in influenza vaccine selection, and vaccination remains effective well beyond the ideal September-to-October window.
|Articles|April 19, 2022
Daily OTC Pearl: Theraflu
Author(s)Saro Arakelians, PharmD
Theraful is a cold and flu medication that may help to relieve symptoms such as congestion, sore throat, aching, and fever.
Advertisement
OTC/Lifestyle Pearl of the Day: Theraflu
Indication: Theraful is a cold and flu medication that may help to relieve symptoms such as congestion, sore throat, aching, and fever.
Insight:
- Can be taken every 4 hours while symptoms persist. Do not take more than 6 packets in 24 hours unless directed by a physician.
- Theraflu helps fight nasal and sinus congestion, cough, body aches, sore throat pain, headache, and fever.
- Dissolve a single packet of flavored powder into hot water.
- Ingredients: Acesulfame potassium, anhydrous citric acid, aspartame, D&c Yellow No. 10, Fd&c Blue No. 1, Fd&c Red No. 40, flavors, maltodextrin, silicon dioxide, sodium citrate, sucrose, tribasic calcium phosphate.
Source:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague and which antibiotics the CDC recommends.
A meta-analysis of 27 trials found 15% lower cardiovascular (CV) event risk per 10-mm Hg SBP reduction, with eGFR declines but no rise in kidney failure.
As earning years peak, so do spending and responsibility—here’s where midcareer pharmacists should focus their financial decision-making.
In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.
Post hoc STEP UP data at EASD 2026 show liver fat fell from 8.8% to 3.1% at 72 weeks in a 55-person MRI subgroup, though no placebo comparison was reported.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pneumonic Plague: Symptoms, Antibiotics, and Current US Risk
2
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
3
Intensive BP Control Cuts CV Risk Regardless of CKD Status
4
Inside the New Consensus Recommendations for Acute Stroke Care
5